The lowering of the price target from $9 to $8 by Leerink Partners suggests a less optimistic view on the stock's potential, which could lead to a negative short-term impact on RXRX's stock price. The Market Perform rating indicates that the stock is expected to perform in line with the market, but the reduced price target may cause some investors to reassess their positions.